Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

VOLUNTARY ANNOUNCEMENT

SIRNAOMICS RECEIVED FDA SPECIFIC GUIDANCE FOR FURTHER DEVELOPMENT OF STP705 FOR TREATMENT OF SQUAMOUS CELL CARCINOMA IN SITU

The board (the "**Board**") of directors (the "**Directors**") of Sirnaomics Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**Sirnaomics**") hereby informs the shareholders and potential investors of the Company of the attached press release that the Group has received specific guidance from the U.S. Food and Drug Administration for further development of the Company's novel siRNA therapeutic, STP705, for the treatment of Squamous Cell Carcinoma in situ (isSCC).

This announcement is made by the Company on a voluntary basis. The Group cannot guarantee that STP705 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, April 16, 2024

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai and Dr. David Mark Evans as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.

Sirnaomics Received FDA Specific Guidance for Further Development of the Company's Novel siRNA Therapeutic, STP705, for Treatment of Squamous Cell Carcinoma *in situ*

Hong Kong SAR | Germantown, MD, USA | Suzhou Biobay, China, April 16, 2024 — Sirnaomics Ltd. (the "**Company**", stock code: 2257, together with its subsidiaries, the "**Group**" or "**Sirnaomics**"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Company has received the U.S. Food and Drug Administration (FDA)'s written responses to a requested Type C meeting for further development of its novel siRNA therapeutic, STP705, for treatment of Squamous Cell Carcinoma in situ (isSCC).

The purpose of the requested Type C meeting is to obtain FDA's advice and comments on the proposed non-clinical and clinical development plans in preparation for Phase II/III and Phase III clinical studies for the treatment of isSCC. In response to the Company's proposal and questions regarding the relevant non-clinical studies and clinical study design, the FDA has provided a clear path forward with specific guidance for both non-clinical and clinical studies, modifications to the proposed Phase II/III and Phase III clinical studies and further justification required for using two active components in the drug candidate STP705. Currently, the Company is already initiating the requested preclinical studies according to the FDA's guidance.

Dr. Patrick Lu, Founder, Chairman of the Board, Executive Director, President, and Chief Executive Officer of Sirnaomics stating, "we are thankful for the FDA's specific guidance at the experimental detailed level that will allow for a more efficient development process for advancing our novel siRNA therapeutics platform into the late-stage clinical development. I am confident that a clinical dosing regimen-related preclinical study, some modifications to our proposed Phase II/III study and other related efforts will provide solid foundation for a later Phase III clinical study of STP705 for treatment of non-melanoma skin cancer."

About STP705

Sirnaomics' leading product candidate, STP705, is an siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the FDA and the Chinese National Medical Products Administration (NMPA), including treatments of cholangiocarcinoma (CCA), non-melanoma skin cancer and hypertrophic scar. There are currently three product pipeline programs prioritized for STP705: the most advanced in isSCC, a completed Phase II for Basal Cell Carcinoma (BCC) and a Phase I for focal fat remodeling. For other indications, STP705 has received Orphan Drug Designation for the treatment of CCA and primary sclerosing cholangitis (PSC) from the FDA.

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Company has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 (Phase IIa, IIb) and STP707 (Phase I). The ongoing Phase I study of STP122G represents the first drug candidate of GalAhead™ technology entering clinical development with an encouraging therapeutic efficacy and safety readouts for the first two cohorts. Learn more at: www.sirnaomics.com.

CONTACT:

Investor Relations:
Johnson Shen
Email: johnsonshen@sirnaomicschina.com

Asia Media Contact:
Phoenix Fung
Tel: +852 2114 4939
Email: sprg_sirnaomics@sprg.com.hk